Ultragenyx Pharmaceutical
RARE
#4141
Rank
โ‚น285.54 B
Marketcap
โ‚น2,899
Share price
-0.32%
Change (1 day)
-6.69%
Change (1 year)

Revenue for Ultragenyx Pharmaceutical (RARE)

Revenue in 2026 (TTM): โ‚น59.80 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current revenue (TTM ) is โ‚น63.30 Billion. In 2025 the company made a revenue of โ‚น60.38 Billion an increase over the revenue in the year 2024 that were of โ‚น48.06 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚น59.80 B-0.97%
2025 โ‚น60.38 B25.65%
2024 โ‚น48.06 B32.94%
2023 โ‚น36.15 B20.24%
2022 โ‚น30.06 B14.95%
2021 โ‚น26.15 B31.96%
2020 โ‚น19.82 B168%
2019 โ‚น7.39 B105.41%
2018 โ‚น3.60 B2058.95%
2017 โ‚น0.16 B1745.3%
2016 โ‚น9.03 M
2015 N/A
2014 N/A
2013 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Lexicon Pharmaceuticals
LXRX
โ‚น6.69 B-89.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
โ‚น28.71 B-54.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
โ‚น59.95 B-5.30%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚น306.49 B 384.14%๐Ÿ‡บ๐Ÿ‡ธ USA